PRESS INFORMATION BUREAU
पत्र सूचना कार्यालय
GOVERNMENT OF INDIA
भारत सरकार

Financial Express, Delhi
Thursday 30th January 2014, Page: 7
Width: 7.81 cms, Height: 12.33 cms, a4, Ref: pmin.2014-01-30.47.54

Ranbaxy's Toansa trouble: EU, UK studying findings

Hyderabad, Jan 29: Days after the US FDA banned imports of Ranbaxy products into America from the Toansa plant, health regulators of EU and the UK said they are evaluating the FDA inspection findings to assess if deviations from GMP have any implication for their markets.

European Medicines Agency (EMA), a body under the EU, said Ranbaxy Laboratories site in Toansa, Punjab is a supplier of active ingredients for four centrally authorised medicines Enyglid (repaglinide), Repaglinide Krka (repaglinide), Repaglinide Teva (repaglinide) and Nevirapine Teva (nevirapine), besides several non-centrally authorised medicines.

"The EMA and national medicines authorities in the EU have been informed of the recent FDA inspection findings and prohibition of importation or distribution within the US of active pharmaceutical ingredients from Ranbaxy Laboratories' site in Toansa, India, due to deviations from Good Manufacturing Practice (GMP) identified during the inspection in Toansa," EMA said in an email. *PTI*

Regulatory.